Literature DB >> 27717649

Correlation of clinical, laboratory and drug susceptibility profiles in 176 patients with culture positive TBM in a tertiary neurocare centre.

Kavitha Kumar1, Prashant Giribhattanavar1, Nagarathna Chandrashekar1, Shripad Patil2.   

Abstract

Drug resistance has increased the difficulties in control of tuberculosis infection. The present study evaluated the clinical and laboratory features among tuberculous meningitis (TBM) patients and the drug susceptibility of Mycobacterium tuberculosis (M.tb) isolated from CSF. Out of 698 CSF samples, 176 (25.21%) were M.tb culture positive. Among the clinical signs and symptoms, fever, headache and altered sensorium were found to be statistically significant (P<0.05). ELISA was a better predictor of disease and found to be statistically significant (P<0.001) in culture-proven TBM cases. Totally, 57 (32.4%) isolates were resistant to one or more drugs that include 5 (2.8%) multidrug-resistant isolates. In conclusion, the search for antibody in CSF and also CSF chloride can represent as an adjunct in the diagnosis of TBM. Screening of drug susceptibility is a very important factor and would help in better management of the disease.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cerebrospinal fluid; Culture; Diagnosis; Drug resistance; Immunoassay; Mycobacteria

Mesh:

Substances:

Year:  2016        PMID: 27717649     DOI: 10.1016/j.diagmicrobio.2016.09.018

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  2 in total

1.  The application of IS6110-baced loop-mediated isothermal amplification (LAMP) in the early diagnosis of tuberculous meningitis.

Authors:  Wen-Wen Sun; Qin Sun; Li-Ping Yan; Qing Zhang
Journal:  Oncotarget       Date:  2017-02-25

Review 2.  Microbiological diagnosis of tuberculous meningitis: Phenotype to genotype.

Authors:  Ravindra Kumar Garg
Journal:  Indian J Med Res       Date:  2019-11       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.